European Medicines Committee Backs Johnson & Johnson's COVID-19 Booster Dose

Comments
Loading...
  • EMA's human medicines committee (CHMP) has concluded that a booster dose of Johnson & Johnson's PFE COVID-19 vaccine may be considered at least two months after the first dose in people aged 18 years and above.
  • The recommendation follows data showing that a booster dose of COVID-19 vaccine given at least two months after the first dose in adults led to a rise in antibodies against SARS-CoV-2.
  • The risk of thrombosis combined with thrombocytopenia (TTS) or other very rare side effects after a booster is not known and is being carefully monitored. 
  • CHMP also concluded that a booster dose with COVID-19 vaccine might be given after two doses of one of the mRNA vaccines authorized in the EU, Comirnaty, from Pfizer Inc PFEBioNTech SE BNTX or Spikevax, from Moderna Inc MRNA.
  • Related Link: Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab.
  • Price Action: JNJ shares are up 0.19% at $170.62 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!